Vitamin K2 going mass market

Join Kappa Bioscience and a panel of industry experts who will discuss and answer questions about launching successful K2 products

The unparalleled bone and heart benefits of vitamin K2 MK-7 have opened doors to mass market consumers. More and more K2 products are being launched, with companies and marketers looking to gain first-mover advantage.

The roundtable discussion and Q&A will cover the following:

  • K2 science
  • market opportunity
  • commercial risks
  • formulation
  • galenics
  • stability and quality
  • analysis.

K2 is ready for mass markets. Join Kappa Bioscience to learn how to profit from the enormous potential of vitamin K2 MK-7.


  • Egil Greve President & CEO at Kappa Bioscience
  • Morgan Laloux Business Development Manager Health and Nutrition Southern Europe at Capsugel
  • Scott Colbourne Business Manager NSW, Food & Pharmaceutical at ALS Pharmaceutical Australia
  • Jim Bornhold Executive VP of Nutraceuticals at Chemroy Canada
  • Bjarne Bloch Medical Advisor at Orkla Care A/S
  • Jörg Büttinghaus VP Sales & Marketing at Kappa Bioscience

Interested in attending the event: The Experts Discuss: Successful Product Launches, click here to register

Featured Companies

Kappa Bioscience (more information, website)